Guidelines for making it easier to test for a gene that affects drug reactions.

The AMP has published recommendations to enhance DPYD genotyping assays for clinical testing to improve patient care.

• The Association for Molecular Pathology (AMP) has published consensus recommendations to assist in the design and validation of clinical DPYD genotyping assays.
• The recommendations aim to standardize testing across laboratories and improve patient care.
• The AMP Clinical Practice Committee’s Pharmacogenomics (PGx) Working Group developed these recommendations for clinical testing.
• The report focuses on DPYD genotyping, which can identify individuals at risk for severe fluoropyrimidine-related toxicity.
• The recommendations provide a tiered categorization of variants for clinical testing, with Tier 1 having a well-characterized effect on protein function, while Tier 2 includes optional variants meeting some criteria.

Please leave this field empty

Stay Informed with the Latest Health News!

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.